Jagsonpal Net Income From Continuing Ops from 2010 to 2024
| JAGSNPHARM | 636.65 9.80 1.52% |
Net Income From Continuing Ops | First Reported 2016-12-31 | Previous Quarter 35.5 M | Current Value 53.3 M | Quarterly Volatility 36.5 M |
Check Jagsonpal Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jagsonpal Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 14.6 M, Interest Expense of 7.7 M or Total Revenue of 1.8 B, as well as many indicators such as . Jagsonpal financial statements analysis is a perfect complement when working with Jagsonpal Pharmaceuticals Valuation or Volatility modules.
Jagsonpal | Net Income From Continuing Ops |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Jagsonpal Stock
Jagsonpal Pharmaceuticals financial ratios help investors to determine whether Jagsonpal Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Jagsonpal with respect to the benefits of owning Jagsonpal Pharmaceuticals security.